ANAB: Morgan Stanley Files 13G for 1.85M Shares, 6.3% Ownership

Rhea-AI Filing Summary

Morgan Stanley and its subsidiary Morgan Stanley Capital Services LLC filed a Schedule 13G on 08/05/2025 disclosing a combined passive stake of 1,845,002 ANAB shares (6.3 % of outstanding) as of 06/30/2025. The parent company reports shared voting power over 1,841,919 shares and shared dispositive power over 1,845,002 shares; it holds no sole voting or dispositive authority.

The subsidiary individually owns 1,525,502 shares (5.2 %) with fully shared voting and dispositive power. The filing is made under Rule 13d-1(b), classifying Morgan Stanley as a parent holding company/control person (HC, CO) and the subsidiary as a broker-dealer (BD, CO). Both certify the shares were acquired in the ordinary course of business and not for the purpose of influencing control of AnaptysBio.

Positive

• Morgan Stanley now holds 6.3 % of ANAB’s outstanding shares, introducing a prominent institutional investor and potential liquidity support.
• Filing is passive (Rule 13d-1(b)), indicating no immediate risk of activist pressure while still signalling confidence in the company.

Negative

• None.

Insights

Securities Analyst

TL;DR – Morgan Stanley reveals 6.3 % passive stake, adding a high-profile institutional holder to ANAB’s register.

Morgan Stanley’s aggregate ownership crosses the 5 % threshold, triggering this 13G. A globally recognised financial institution taking a >6 % position can boost market confidence, increase trading liquidity and widen sell-side coverage for AnaptysBio. Because the filing is passive (13G, not 13D), no immediate strategic activism is implied. Still, passive stakes by sophisticated investors are often viewed positively by the market, especially for mid-cap biotechs that rely on external capital. The reported holding date (30 Jun 2025) precedes the filing by just over a month, so the data are relatively current. Impact: modestly positive.

Corporate Governance Expert

TL;DR – No control intent signalled; governance impact minimal.

The 13G certification states the shares were not bought to influence control, and Morgan Stanley claims only shared voting/dispositive power. Hence, no governance contest or board nomination pressure is expected. From a compliance standpoint, both entities correctly identify their legal classifications and provide required joint-filing exhibits. Investors should monitor future amendments: a switch to Schedule 13D or an increase above 10 % would materially change the governance outlook. Present impact: neutral-to-positive because of enhanced institutional oversight without activism.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

ANAPTYSBIO, INC

(Name of Issuer)

Common Stock

(Title of Class of Securities)

032724106

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 032724106

1

Names of Reporting Persons

Morgan Stanley

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,841,919.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,845,002.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,845,002.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.3 %

12

Type of Reporting Person (See Instructions)

HC, CO

SCHEDULE 13G

CUSIP No. 032724106

1

Names of Reporting Persons

Morgan Stanley Capital Services LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,525,502.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,525,502.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,525,502.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

BD, CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ANAPTYSBIO, INC
(b)	Address of issuer's principal executive offices: 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA, 92121
Item 2.
(a)	Name of person filing: 1: Morgan Stanley 2: Morgan Stanley Capital Services LLC
(b)	Address or principal business office or, if none, residence: 1: 1585 Broadway, New York, NY 10036 ;2: 1585 Broadway, New York, NY 10036
(c)	Citizenship: 1: Delaware 2: Delaware
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 032724106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).
(b)	Percent of class: 6.3 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
	(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).
	(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).
	(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Morgan Stanley

Signature:	Christopher O'Hara
Name/Title:	Authorized Signatory, Morgan Stanley
Date:	08/05/2025

Morgan Stanley Capital Services LLC

Signature:	Christopher O'Hara
Name/Title:	Authorized Signatory, Morgan Stanley Capital Services LLC
Date:	08/05/2025

Exhibit Information

EXHIBIT NO. EXHIBITS ------------------ ------------------------------------ 99.1 Joint Filing Agreement 99.2 Item 7 Information * Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).

FAQ

How many AnaptysBio (ANAB) shares does Morgan Stanley own?

1,845,002 common shares are beneficially owned in total.

What percentage of AnaptysBio’s outstanding stock is held by Morgan Stanley?

The filing reports 6.3 % of the outstanding common shares.

When was the ownership position effective?

The shares were held as of 06/30/2025.

Under which SEC rule was the Schedule 13G filed?

It was filed pursuant to Rule 13d-1(b), covering passive institutional investors.

Does Morgan Stanley intend to influence control of AnaptysBio?

No. The certification states the stake is held in the ordinary course of business with no intent to influence control.

What are the classifications of the reporting persons?

Morgan Stanley is a parent holding company/control person (HC, CO); Morgan Stanley Capital Services LLC is a broker-dealer (BD, CO).